REMARKS

The specification has been amended herein for trademarks in capital letters and accompanied by the generic terminology.

Claims 1-27 have been canceled without prejudice. Applicant reserves the right to prosecute the subject matter of any canceled claims in one or more continuation, continuation-in-part, or divisional applications. Claims 28-42 have been added to recite a method of treating Parkinson disease using specific selective cytokine inhibitory drugs. The claims are supported by canceled claims 1-13, and the originally filed specification (e.g., paragraphs [0327] to [0337], [414] and [421]) and application no. 10/798,317, which is incorporated by reference in paragraph [0327] of the specification. No new matter is added by these amendments. Entry of the amendments is respectfully requested.

Applicant respectfully requests that the present remarks be made of record in the file of the present application. No fee is believed due. However, if the Examiner determines that any fee is due, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date:

July 23, 2008

(Reg. No. 52,042)

Fof: Anthony M. Insogna

(Reg. No. 35,203)

JONES DAY

222 East 41st Street New York, New York

10017

(212) 326-3939